| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chairman of the Board and CEO | CEO and Chairman of the Board | Director, Chairman +5 more
5 companies
Brent L Saunders is Director, Chairman at SKIN and has filed Form 4s across 5 companies. Brent L Saunders's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $91.0M at current prices.
Historically, Brent L Saunders's trades have earned a middling insider score of 52/100 across 7 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +6.2%.
The biggest single holding is SKIN (~$62.0M) as Director, Chairman. Net of sales, the SKIN filings show accumulation of 99,830 shares.
Brent L Saunders has 39 Form 4 filings on record from December 2018 to August 2026, across 5 companies: Chairman of the Board and CEO at Bausch + Lomb (BLCO), 2024–2026; Director at ARS Pharmaceuticals (SPRY), 2022–2026; Director, Chairman at Beauty Health (SKIN), 2020–2025, and 2 more.
The 58 reported transactions were 18 stock awards, 15 option or other derivative awards, 14 tax withholdings and 6 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 6 purchases worth about $1.7M and 1 sale worth about $1.7M.
The largest open-market purchase was 32,250 shares of BLCO at an average $15.66 on August 5, 2024, about $505K. Twelve months later BLCO was down 6%.
The only open-market sale was 120,000 shares of SPRY at an average $14.25 on May 20, 2025, about $1.7M. Twelve months later SPRY was down 46%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | BLCO Bausch + Lomb Corporation | CEO and Chairman of the Board | Buy | 14,700 | $17.14 | $251,958.00 | +1.5% | -10.0% | - | |
| May 22, 2025 | BLCO Bausch & Lomb Corp | CEO and Chairman of the Board | Buy | 22,000 | $11.28 | $248,072.00 | +3.2% | +29.2% | +41.5% | |
| May 20, 2025 | SPRY Ars Pharmaceuticals, Inc. | Director | Sale+OE | 120,000 | $14.25 | $1,710,024.00 | - | -2.1% | -45.6% | |
| Aug 12, 2024 | SKIN Beauty Health Co | Director, Chairman | Buy | 40,450 | $1.08 | $43,686.00 | +0.7% | +36.4% | +79.8% | |
| Aug 5, 2024 | BLCO Bausch & Lomb Corp | CEO and Chairman of the Board | Buy | 32,250 | $15.66 | $505,067.25 | +5.7% | +29.0% | -6.2% | |
| Aug 16, 2023 | SKIN Beauty Health Co | Director, Chairman | Buy | 59,380 | $6.10 | $362,372.39 | +1.0% | -76.9% | -76.8% | |
| Dec 29, 2021 | BBIO Bridgebio Pharma, Inc. | Director | Buy | 17,600 | $14.48 | $254,879.68 | New | -23.5% | -46.7% |